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Abstract
HLA-E presented antigens are interesting targets for vaccination given HLA-Es’ essentially 
monomorphic nature. We have shown previously that Mycobacterium tuberculosis (Mtb) peptides 
are presented by HLA-E to CD8+ effector T cells, but the precise phenotype and functional 
capacity of these cells remains poorly characterized. We have developed and utilized in this study 
a new protocol combining HLA-E tetramer with intracellular staining for cytokines, transcription 
factors and cytotoxic molecules to characterize these cells in depth. We confirm in this study the 
significantly increased ex vivo frequency of Mtb-peptide/HLA-E-TM+ CD8+ T cells in the 
circulation of patients with active tuberculosis (TB). HLA-E restricted CD8+ T cells from TB 
patients produced more IL-13 than cells from controls or subjects with latent tuberculosis infection 
(LTBI). Compared to total CD8+ T cells, HLA-E restricted cells produced more IFNγ, IL-4, 
IL-10, and granulysin but less granzyme-A. Moreover, compared to “classical” Mtb specific HLA-
A2 restricted CD8+ T cells, HLA-E restricted CD8+ T cells produced less TNFα and perforin, but 
more IL-4. In conclusion, HLA-E restricted- Mtb specific cells can produce Th2 cytokines 
directly.
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Introduction
An estimated one fourth of the global population is infected with Mycobacterium 
tuberculosis (Mtb) [1]. According to WHO Global Tuberculosis control report 2016, there 
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were 10.4 million new tuberculosis (TB) cases and 1.8 million TB deaths in 2015, including 
deaths resulting from TB disease among HIV-positive people [2].
TB is a potentially lethal disease, but curable if properly treated[2]. M. bovis BCG-
vaccination protects infants from severe and disseminating TB, particularly TB-meningitis 
and military TB [3] but has poor efficacy against pulmonary TB in adults. A novel, effective 
TB vaccine is urgently required and its design depends on a detailed understanding of what 
exactly controls host immune protection.
Over recent years it has become evident that many cell subsets are involved in immune 
protection. Antigen-specific CD8+ effector T cells are detectable in most Mtb infected 
subjects and animals [4]. Depletion of CD8+ T cells in mice reduced survival after infection 
with Mtb, demonstrating their essential role in protection against TB [5]. Similarly, also 
MHC class I knockout mice showed an enhanced sensitivity to Mtb infection [6]. In humans, 
both “classical” class Ia (HLA-A,-B and -C) and “non-classical” class Ib (HLA-E,-F and -G) 
HLA molecules are known to activate CD8+ T cells by presenting cognate peptide to the 
TCR. MHC class Ia molecules can present endogenous, cytoplasmic antigens as well as 
exogenous antigens which are “cross-presented” by dendritic cells [7], including antigens 
derived from intracellular bacteria or viruses [8–11]. Mtb-specific CD8+ T cells in the blood 
of Mtb infected individuals differ in frequency, phenotype and functional activities in 
patients with active TB compared to subjects with latent tuberculosis infection (LTBI) [12, 
13].
HLA-E is a highly conserved MHC class Ib molecule with rather unique properties. 
Primarily HLA-E is involved in prevention of lysis by NK cells through ligation with 
NKG2/CD94 complex. Moreover, HLA-E can also present antigens to CD8+ T cells and 
thus plays a role in both innate and adaptive immunity [11]. Its low allelic variability 
positions it as an interesting candidate antigen presenting molecule for peptide based 
vaccination [11,14]. HLA-E comprises four alleles (E*01:01; E*01:03; E*01:04; E*01:05), 
but only the first two are expressed as functional proteins. HLA-E*01:01 and *01:03 differ 
in a single amino acid outside the peptide binding groove, therefore they are anticipated to 
have a very similar peptide binding profile [15–17]. HLA-E is enriched in Mtb phagosomes 
compared to class Ia molecules and accessible for loading with Mtb peptides [18]. In 
addition to HLA-E’s low allelic variation, another advantage is that HLA-E is not down-
regulated by the HIV-nef protein, as opposed to HLA class Ia molecules [19, 20]. In fact, 
certain components of HIV may even stabilize HLA-E cell surface expression to prevent NK 
mediated lysis of HIV infected cells [21].
In a first study we showed that Mtb peptides were presented by HLA-E to CD8+ T cells 
from LTBI as well as BCG-vaccinated donors. These T cells had both cytolytic and 
immunoregulatory activities [14]. In subsequent work we demonstrated that HLA-E-
restricted clonal CD8+ T cells were able to inhibit Mtb outgrowth in infected human 
macrophages [22]. Qa-1, the mouse homolog of HLA-E, can also present Mtb derived 
antigens during infection [23]. Mice that lack Qa-1, are more susceptible to Mtb infection 
and this increased susceptibility to progress to disease was due to dysregulated T-cell 
responses [23].
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HLA-E-restricted CD8+ T cells circulated in higher frequencies in the blood of active TB 
patients [14, 22, 24] compared to LTBI [15, 22, 24] and were associated with a Th2 cytokine 
profile, notably IL-13. However, although we detected production of Th2 cytokines in 
response to specific Mtb peptide stimulation, and Mtb peptide driven type-2 cytokine 
production was most abundant in donors with strong tetramer staining [22, 24], we were 
unable to demonstrate that HLA-E restricted CD8+ T cells were the source of these 
cytokines. In the current study combine Mtb-peptide/HLA-E tetramer staining with 
intracellular cytokine staining in active TB and LTBI subjects, to demonstrate that HLA-E-
restricted CD8+ T cells actively produce type-2 cytokines. These results provide important 
new evidence on the role of HLA-E restricted CD8+ T cells in human infectious disease.
Results
Ex vivo analysis
Direct ex vivo binding of HLA-E tetramers (TM) loaded with p62 and p68 Mtb- peptides to 
CD8+ T cells was analyzed in peripheral blood mononuclear cells (PBMCs) of 26 tuberculin 
(PPD)-negative healthy subjects (HDs), 14 LTBI subjects, 24 patients with active TB and 5 
HIV-TB co-infected patients (for detailed characteristics see Table 1).
The gating strategy used to select TM+ CD8+ T cells is shown in Fig. 1A and comprised of 
sequential gating on single cells, live cells, lymphocytes, CD3+ cells and CD8+/CD4− cells. 
The CD94 blocking mAb was always included in the staining procedure to prevent HLA-E 
tetramer binding to the NKG2A/CD94 complex. Furthermore, an HLA-E CMV TM was 
included to exclude cells with aspecific binding. By definition T cells have single 
specificities and thus cells binding different TMs cannot do so through cognate TCR 
interactions and thus all double positive cells were excluded and only single Mtb-HLA-E 
TM+ cells were analyzed. Examples of TM staining for HD, LTBI, TB, and TB-HIV are 
shown and illustrate the variation in HLA-E TM binding (Fig. 1B).
Confirming our own previous work, the ex vivo frequency of HLA-E-/Mtb-peptide TM+ 
CD8+ T cells was higher in patients with active TB than in HDs (p <0.0001) (Fig. 1C). As 
expected, the highest frequency of TM+ CD8+ T cells was found in the 5 HIV-TB patients (p 
= 0.0004 versus HD). Donors with LTBI showed a wide array of TM staining, but only a 
small proportion had a high frequency of HLA-E/Mtb TM+ cells. The median values of TM+ 
CD8+ T-cell frequencies were 0.22, 0.23, 0.89, and 1.9% in HDs, LTBI subjects, active TB 
and HIV-TB co-infected patients, respectively (Fig. 1C).
Thus, Mtb-peptide TM binding was highest to CD8+ T cells of patients with active TB and 
even increased with concomitant HIV infection.
Memory phenotypes of HLA-E-/Mtb-peptide TM+ CD8+ T cells
Next, the memory phenotype of HLA-E/Mtb-peptide TM+ CD8+ T cells was analyzed using 
CCR7 and CD45RA. To assess discrete populations rather than single cells, only samples 
with at least 100 TM+ events were included for memory subset analysis. Application of this 
cut-off permitted analysis of 16 out 26 HDs, 11 out 14 LTBI, 20 out 24 TB and 5 out 5 HIV-
TB patients. The majority of circulating HLA-E/Mtb-peptide TM+ CD8+ T cells had an 
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effector-memory profile, both TEMRA and TEM (p = 0.049) phenotypes were prominent in 
TB patients compared to HDs. In contrast, HLA-E/Mtb-peptide TM+ CD8+ T cells with a 
TEMRA phenotype were the most abundant in TB-HIV co-infected patients compared to 
other groups (Fig. 1D).
To characterize HLA-E restricted cells functionally in more depth, CD8+ T cells were 
expanded and stained with specific TMs combined with intracellular markers. Only few 
samples could not be included due to low cell yields or poor expansion; 26 out 26 HDs, 12 
out 14 LTBI and 17 out 24 active TB were included. Of note but not unexpectedly, cells 
from the TB-HIV group were relatively impaired in their growth in culture, therefore only 
TM frequencies are shown but not the functional characteristics of these cells.
The median HLA-E TM+ CD8+ T-cell frequencies were 0.13,0.14, 0.34, and 0.23% in the 
blood of HDs, LTBI subjects, TB and HIV-TB co-infected patients, respectively. Thus, 
following Mtb peptide expansion the frequencies of HLA-E-TM+ Mtb-specific CD8+ T cells 
remained higher in active TB compared to LTBI and HDs. However it considerably 
decreased in TB-HIV co-infected patients, probably due to the poor expansion and survival 
of the cells in culture (Fig. 2A and B). In general, expansion resulted in a significant 
amplification of the number of TM+ cells to allow detailed characterization of their 
functional properties (Fig. 2C). The average TM+ cell counts increased from 750 directly ex 
vivo (for 24 active TB patients) to 4418 after expansion (for 17 TB patients), leading to an 
average expansion of 4.89-fold.
Phenotype after expansion of HLA-E-/Mtb-peptide TM+ CD8+ T cells
Previous characterization of T-cell receptors (TCR) recognizing the CMV UL40 epitope in 
HLA-E had revealed a strong preferential usage of the TCR variable β-region 16 (Vβ16) and 
it was suggested that expression of the Vβ16 TCR fragment was a hallmark of HLA-E 
restricted T cells [25]. Therefore we assessed the expression of Vβ16 on HLA-E- Mtb- 
specific CD8+ T cells. Although Vβ16 staining was observed in the total CD8+ T-cell 
population, we did not observe any preferential Vβ16 usage by TM+ CD8+ T cells in any of 
the study groups (Fig. 2D), showing that HLA-E/Mtb-specific CD8+ T cells have a clearly 
different TCR-Vβ repertoire compared to the previously published HLA-E/CMV-specific 
CD8+ T cells.
We next evaluated the memory phenotypes of the expanded HLA-E TM+ CD8+ T cells of 14 
out 26 HDs (10 Dutch and 4 Italian), 6 out 13 LTBI, 15 out 17 TB, that had more than 
>1000 TM+ events. Memory profile analysis of TM+ CD8+ T cells upon stimulation was not 
significantly different between TEMRA, naïve (TN), effector memory (TEM) and central 
memory (TCM) compartments. HLA-E TM+ CD8+ T cells with an effector phenotype were 
the main population in all groups, consistent with the in vitro expansion (Fig. 2E). When 
compared to the ex vivo memory distribution we observed consistently more TEM and less 
TN, which fits with the expansion observed in the cultures. TEMRA and TCM frequencies 
were not different from ex vivo after the in vitro expansion.
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Cytokine profile of HLA-E/Mtb- specific CD8+ T cells
We evaluated expression of cytokine as well as cytotoxic molecules by intracellular staining 
of HLA-E/Mtb TM+ CD8+ T cells (Fig. 3A). Peptide stimulated cells are shown in 
comparison with unstimulated, but expanded cells. In general, TM+ cells produced both Th2 
and Th1 cytokines as well as IL-10, and TM+ cells from the different clinical groups 
appeared relatively similar. TM+ CD8+ T cells from active TB patients produced more TNF-
α and IL-13 compared to healthy controls (Fig. 3B). Approximately 30% of TM specific 
CD8+ T cells produced IFNγ in HDs, LTBI, active TB groups. Also transcription factors for 
the different lineages were expressed by HLA-E restricted CD8+ T cells. GATA3 was 
expressed more frequently in donors with LTBI (p = 0.042; Fig. 3C). Cytolytic molecules 
were expressed in most TM+ cells, however the range of expression between individuals was 
quite large and different combinations of cytolytic molecules were expressed between 
different individuals (Fig. 3D).
To investigate the relative specific properties of HLA-E-Mtb TM+ CD8+ T cells we 
compared them to the total pool of CD8+ T cells in terms of functional profiles and across 
all groups (Fig. 4); TB patients only are shown in Supporting Information Fig. 1 to show the 
relative abundance of specific cytokines in this group. HLA-E TM+ cells expressed 
significantly more IFN-γ compared to total CD8+ T cells in all samples (p < 0.0001; TB 
patients only p = 0.0127). Also IL-4 was detected at a higher frequency in the HLA-E TM+ 
populations compared to the total CD8+ T cells (p <0.0101), as was IL-10 (p <0.0001; TB 
patients only p = 0.0001) (Fig. 4A). TNF-α and IL-13 were not significantly differently 
expressed in the expanded TM+ cells compared to the total CD8+ T-cell population.
In agreement with these data, the frequency of TM+ CD8+ T cells expressing T-bet, Gata3 
and FoxP3 was higher compared to the total CD8+ T cells (T-bet p < 0.0001, TB samples 
only p = 0.0003; Gata3 p = 0.0009, TB samples only p = 0.0012; FoxP3 p <0.0001, TB 
samples only p = 0.0012) (Fig. 4B).
CD8+ T cells producing Granulysin (Gnly) were significantly increased in the TM+ 
population compared to total CD8+ T cells, while a decrease occurred in Granzyme A 
(GzmA) in TM+ CD8+ T cells (Gnly p < 0.0001, TB samples only p = 0.049; GzmA p = 
0.0091, TB samples only p = 0.0002;) (Fig. 4C). Granzyme B (GzmB) and perforin (PRF) 
levels were not different between total and TM+ CD8+ T cells.
Comparison of HLA-E restricted CD8+ T cells to HLA-A2 restricted Mtb specific CD8+ T 
cells
Finally, we compared the functional phenotypes of “non-classical” HLA-E restricted Mtb-
specific CD8+ T cells to that of “classical” HLA-A2 restricted, Mtb-specific CD8+ T cells in 
the same samples (Fig. 5). All donors were typed for HLA-A*0201 using specific antibody 
staining on PBMCs: 3 out 26 HDs, 3 out 13 LTBI and 7 out 17 TB patients were HLA-
A*0201+. For Panel A (including cytokines) 7 out 17, and for Panel B (including cytotoxic 
molecules and IL-10) 6 out 17 active TB patients were analyzed after re-stimulation with 
HLA-E presented Mtb p62 and p68 peptides or with HLA-A2 presented Mtb-Ag85B 
peptides p74 and p79 (characteristics of Mtb-peptides: Table 2). The frequency of HLA-E-
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restricted CD8+ T cells producing TNF-α was lower than that of HLA-A2-restricted CD8+ T 
cells (all samples, p = 0.0342) (Fig. 5A). Th2 cytokines were more abundantly expressed in 
HLA-E restricted T cells (IL-4, all samples p = 0.0327) (Fig. 5A), especially in TB patients 
(Supporting Information Fig. 2), but this did not reach statistical significance due to the low 
number of HLA-A2+ TB patients that could be analyzed. In contrast, Tbet and FoxP3 
expression was higher in HLA-E-restricted CD8+ T cells compared to HLA-A2-restricted 
CD8+ T cells (T-bet, all samples, p = 0.0017; FoxP3, all samples, p = 0.0012; FoxP3, TB 
patients only, p = 0.0156) (Fig. 5B). CD8+ T cells expressing Perforin (Prf) were higher and 
lower, respectively, in frequency among HLA-E restricted than HLA-A2- restricted Mtb 
specific CD8+ T cells (Prf p = 0.0161) (Fig. 5C). Together these data demonstrate that HLA-
E restricted Mtb specific cells display unique functional properties compared to either total 
CD8+ T cells or HLA-A2 restricted Mtb specific T cells.
Discussion
This is the first comprehensive analysis of human HLA-E restricted CD8+ T cells, 
permitting detailed characterization of functional capacities of these antigen specific cells. 
As we have previously shown [22, 24], PBMCs from TB patients produced significant levels 
of IL-4 and IL-13 following stimulation with HLA-E presented Mtb-peptides. In addition, 
HLA-E restricted Mtb-specific CD8+ T-cell clones displayed an unique Th2-like profile 
(secreting IL-4, IL-5, IL-13) upon peptide stimulation [22]. Although these studies strongly 
suggested an association between HLA-E restricted T cells and the production of Th2 
cytokines, they did not formally prove that circulating HLA-E restricted Mtb specific T cells 
from TB patients produced Th2 cytokines. In this study, we developed a protocol that 
combined tetramer with intracellular (cytokine) staining and that allowed us to describe for 
the first time the characteristics of these unconventional, HLA-E restricted Mtb-specific 
CD8+ T cells in cohorts of active TB patients and LTBI subjects.
Firstly, the direct ex-vivo frequency of HLA-E restricted Mtb-TM+ CD8+ T cells was higher 
in patients with active TB compared to HDs. The majority of these cells had an effector-
memory profile, suggesting that these cells were activated in the circulation of active TB 
patients, in contrast to healthy donors in which these cells mostly had a naïve phenotype. 
Expansion of cells allowed assessment of intracellular cytokines within the TM+ population. 
Most cytokines were expressed at similar levels by HLA-E restricted T cells among the 
different clinical groups. TNFα and IL-13 were abundantly expressed by TM+ CD8+ T cells 
from active TB patients compared to healthy controls. While the lineage-specifying 
transcription factor T-bet associated with Th1 function was expressed by the majority of 
HLA-E- TM+ CD8+ T cells from each group, a higher frequency of Gata3 expression was 
observed in TM+ CD8+ T cells from LTBI subjects. Gata3 expression was also detected 
previously in healthy PPD+ donors’ HLA-E restricted Mtb specific T-cell clones [22]. FoxP3 
was detected in TM+ CD8+ T cells from all groups. CD4+ and CD8+ Tregs were present at 
the site of infection [26–28], and were increased in the circulation of patients with active TB 
compared to healthy controls [26–28]. Tregs were found to suppress T-cell IFN-γ 
production during active TB, which normalized after treatment [29]. In our previous work, in 
vitro stimulation with HLA-E Mtb-peptides p62 and p68 resulted in the induction of 
functionally active regulatory T cells as well as cytolytic effector cells [14]. This dualism of 
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effector versus. immunoregulatory activities of HLA-E restricted T cells was also found for 
the T-cell clones [14, 22]. Not only the cytolytic effector functions but also the 
immunoregulatory properties of HLA-E restricted cells may be important in relation to 
protective immunity, by controlling pathogenic inflammation [23]. A negative consequence 
may be that immunoregulation contributes to pathogen persistence and chronic infection [11, 
30].
A specific TCR fragment, Vβ16, has been associated with the recognition of the CMV UL40 
epitope in the context of HLA-E [25]. However, in contrast to previous suggestions, Vβ16 
was not universally used in TCR mediated recognition of pathogen derived peptides 
presented by HLA-E, since none of our donors preferentially utilized the Vβ16 TCR 
fragment in their Mtb specific HLA-E restricted response. HLA-E-restricted, Mtb-specific 
CD8+ T cells were compared for expression of secreted molecules and transcription factors 
relative to the total CD8+ T-cell population within the same donor. HLA-E TM+ cells 
produced significantly more IFNγ, IL-4 and IL-10 compared to total CD8+ T cells. 
Increased expression of IFNγ and IL-10 in active TB patients may reflect recent activation. 
The frequency of TM+ CD8+ T cells expressing T-bet, Gata3 and FoxP3 was higher than in 
total CD8+ T cells. CD8+ T cells producing Granulysin were significantly higher in the 
HLA-E restricted population compared to total CD8+ T cells, contrasting with the decreased 
frequency of Granzyme A producing TM+ CD8+ T cells. Moreover, Mtb specific CD8+ T 
cells with classical (HLA-A2) and non-classical (HLA-E) restriction were compared. This 
revealed reduced TNF-α and perforin expression in HLA-E restricted T cells, but increased 
expression of T-bet, FoxP3 and IL-4.
During the first period of Mtb infection, key cytokines associated with protection are IFN-γ 
and TNF-α [31, 32]. After clearance or successful containment of Mtb, activated immune 
responses must be ceased to avoid inflammatory damage. This may be mediated by anti-
inflammatory cytokines such as IL-10, IL-13, or by a Th2 environment. This Th1/Th2 
‘switch’ may be antigen-specific, depending on HLA restriction or the stage, early or late in 
infection, in which the antigens are presented [33]. The ex vivo frequency of HLA-E-
restricted CD8+ T cells is higher in active TB but significantly decreased after 6 months of 
chemotherapy whereas the frequencies of HLA-A2-restricted CD8+ T cells increased after 
therapy [24]. This opposite trend of HLA-E and HLA-A2 restricted responses may be 
related to the different roles exerted by the two HLA molecules and by the different set of 
antigens presented during Mtb disease stages. This indicates that although both HLA-A2 
restricted as well as HLA-E restricted CD8+ T cells are Mtb-specific, their restriction 
correlated with different functional properties. Future studies need to resolve the relative 
significance of effector versus. immunoregulatory activities within the HLA-E based antigen 
presentation system in infection and other human diseases.
Materials and methods
Recruited patients
Peripheral blood was collected from a total of 69 adults; 13 healthy donors, 14 with LTBI 
(age range 36–60), 24 with active TB disease (age range 22–38), and 5 with TB-HIV co-
infection (age range 28–40) from the Dipartimento di Medicina Clinica e delle Patologie 
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Emergenti, University Hospital, Palermo, Italy (for patients’ characteristics see Table 1). The 
study was approved by the Ethical Committee of the University Hospital, Palermo, where 
patients were recruited. All patients signed an informed consent and the study was 
performed according to the guidelines of the local ethics committee and in accordance with 
the principles of the Helsinki Declaration and those of “Good Clinical Practices”. All TB 
patients had clinical and radiological findings consistent with active pulmonary TB, the 
diagnosis was confirmed by bacteriological isolation of Mtb. None of the active TB patients 
had been vaccinated with BCG, or were treated with steroid or other immunosuppressive or 
anti-tubercular drugs at the time of sampling.
LTBI subjects were health-care workers with a positive tuber-culin (PPD) skin test and no 
symptoms and signs of active TB [34]. Skin tests were considered positive when the 
induration was larger than 10 mm at 72 h after injection of 5 U of PPD (Statens Serum 
Institut, Copenhagen, Denmark).
Besides the 13 healthy donors mentioned above, an additional 13 PPD negative anonymous 
bloodbank donors (Sanquin Bloodbank, the Netherlands) were recruited; These donors were 
tested for PPD responses in a 6 day lymphocyte-stimulation-assay [35, 36] with IFN-γ 
measurement by ELISA (U-CyTech, Utrecht, the Netherlands) as readout. Donors that 
produced less than 100 pg/mL IFN-γ in response to PPD were considered negative.
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples 
by Ficoll-Hypaque (Sigma) density centrifugation, frozen and stored in liquid nitrogen. 
Frozen samples were sent to the Department of Infectious Diseases at Leiden University 
Medical Center (LUMC) where the experiments were performed.
Preparation of MHC class I tetramers
Extracellular HLA class I, with a C-terminal BirA recognition site, and β2-microglobulin 
were expressed in Escherichia coli as insoluble aggregates in the form of inclusion bodies. 
Purified inclusion bodies were solubilized in urea and folded with peptide by dilution. 
Monomers were biotinylated using the BirA enzyme and purified by gelfiltration on a 
Hiload 16/60 Superdex 75 prep grade.
HLA class I tetramers were generated by adding SA-phycoerythrin (PE) or SA-
allophycocyanin (APC) at an SA:MHC class I molar ratio of 1[2236]6 [37]. To ensure 
maximum saturation of the SA with peptide-MHC monomers (i.e. that tetramers are 
formed), SA was sequentially added in four steps at 20-min intervals. The resulting 
tetramers were stored in PBS, with a final concentration of 16% glycerol, 0,6% BSA, 0,02% 
azide and Complete protease inhibitors (Roche) at −80°C. Tetramers were generated for 
HLA-E*01:03 and HLA-A2*02:01.
The following peptides were used for in vitro stimulation of T cells and/or for TM 
generation: the HLA-E restricted Mtb peptide p62 (RMPPLGHEL), p68 (VLRPGGHFL), 
and CMV UL40 (VMAPRTLLL); the HLA-A2 restricted Ag85 Mtb peptides 
(GLPVEYLQV), (KLVANNTRL), and HIV Gag (SLYNTVATL) [14, 25, 38]. All peptides 
were synthesized by Peptide2.0 Inc (Chantilly, VA, USA).
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PBMCs were thawed, counted (CASY cell counter, Roche, Woerden, The Netherlands) and 
rested for one hour in an incubator at 37°C with 5% CO2. Approximately 106 cells per 
sample were blocked for 10 min at RT with 10 μg/mL purified CD94 mAb (Clone HP-3D9, 
BD Bioscience) to block NKG2A/CD94 binding of HLA-E TMs, and then stained with 
HLA-E TMs for 15 minutes at 37°C. Both p62 and p68 HLA-E- TMs were PE-conjugated 
and merged in the same colour channel. CMV-specific-HLA-E- TM (APC-conjugated) was 
used as control. The CMV-TM was added in the same staining step as the Mtb-specific TMs. 
Table 2 summarizes the peptides and TMs used.
After incubation, samples were washed with PBS/0.1% BSA (Pharmacy LUMC, the 
Netherlands, Sigma-Aldrich, Zwijndrecht, the Netherlands), and stained with live/dead 
marker (Vivid fixable violet dye, Invitrogen, Thermo Fisher Scientific Inc., Bleiswijk, the 
Netherlands) according to the manufacturer’s protocol. Followed by Fluorochrome-
conjugated antibodies: CD3 (Horizon-V500, clone UCHT1), CD8 (AlexaFluor700, clone 
RPA-T8), CD4 (PerCp-Cy5.5, clone RPAT4), CCR7 (PE-Cy7, clone 3D12) (all BDBio-
sciences), and CD45RA (BV570, clone MI100), CD14 (Qdot655, clone TüK4) (both 
Invitrogen). Samples were stained for 30 min at 4°C, washed twice in PBS/0.1% BSA and 
then acquired on a LSRFortessa flow cytometer with Diva software (v6.2, BDBio-sciences). 
A minimum of 1 × 10e6 PBMC were acquired and analysis was performed on at least 100 
000 CD8+ events for each sample.
Data were analyzed with FlowJo software (version 9.9.6 Treestar Inc., Ashland, OR, USA). 
The analysis of each specific subset was performed using the gating strategy shown in Fig. 
1A in compliance with the MIATA guidelines [39].
Generation of HLA-E restricted CD8+ T-cell lines
PBMCs were thawed, counted and 2 × 10e6 PBMCs were expanded in 24-well plates using 
5 μg/mL PHA (Remel, Thermo Fisher Scientific Inc.), in Iscove’s modified Dulbecco’s 
medium (IMDM, Life Technologies-Invitrogen) supplemented with 10% human serum 
(Heat inactivated pooled serum from bloodbank donors) and incubated for 3 days at 37°C, 
5% CO2. Medium was refreshed with 25 CU/mL IL-2 (Proleukin, Novartis Pharma, 
Amsterdam, the Netherlands). After 6 days, CD8+ T cells were sorted by positive bead 
selection (MACS, Miltenyi Biotec BV, Leiden, the Netherlands). Purity of all cells sorts was 
>98% as checked by flow cytometry (FACS Accuri Cytometer, BD Bioscience). Purified 
CD8+ T cells were subsequently stimulated with 10 μg/ml Mtb p62 (RMPPLGHEL) and p68 
(VLRPGGHFL) peptides, recombinant human IL-15 and IL-7 (both 5 ng/mL final 
concentration Peprotech, Rocky Hill, NJ, USA), as well as irradiated (30 Gy) allogeneic 
feeder cells. At day 3, the culture was refreshed with complete IMDM medium with IL-2 
(50 CU/ml). After 5 days, cultures were splitted and refreshed with complete IMDM with 
IL-2 (100 CU/mL). At day 7, cells were harvested and analyzed for tetramers, cytokines and 
surface markers by flowcytometry. Starting with a number of 3 – 4 × 106 PBMCs, the yield 
of CD8+ T cells after this procedure was about 80–100 × 106.
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Intracellular staining (ICS) for flow cytometry
HLA-A2 TM analysis was only performed on donors that were HLA-A*0201, therefore 105 
cells of all samples were typed with an anti-HLA-A2 antibody (FITC, clone BB7.2, 
BDBiosciences).
Expanded CD8+ T cells were stimulated for 6 h with 10 μg/mL Mtb- peptides and analyzed 
after 16 h incubation with BrefeldinA (3 μg/mL, Sigma-Aldrich) and monensin (1:1000, 
BioLegend) at 37°C in 5% CO2. Cells were harvested, washed with PBS/0.1% BSA, and 
blocked for 10 min at RT with a purified CD94 mAb and then stained with tetramers and 
CCR7 (PE-Cy7, clone 3D12, BDBiosciences) for 15 min at 37°C. After incubation, cells 
were washed once in PBS/0.1% BSA and subsequently stained for surface markers (30 min, 
4°C) CD3 (BV570, clone UCHT1, BioLegend), CD8 (Alexa700, clone RPA-T8), CD45RA 
(Qdot655, clone MEM-56, Invitrogen) followed by a fix/perm procedure according to 
manufacturer’s instruction (BDBiosciences). Two different panels for intracellular markers 
were used. Panel A included: T-bet (BV605, clone 4BIO), IL-13 (PerCP-Cy5.5, clone 
JES10–5A2) (both BioLegend); IFN-γ (AlexaFluor700, clone B27), TNF-α (APC-H7, 
clone MAb11), IL4 (PE-C594, clone MP4–25D2), GATA3 (Alex-aFluor488, clone L50–
823) (all BDBiosciences); FoxP3 (PE-Cy5, clone PCH101) (Ebioscience). Panel B: rabbit-
anti-human Granulysin (kind gift of Dr. A. Krensky, Stanford, CA) followed by Goat-anti-
Rabbit-FITC, Perforin (PEC594, clone δG9), Granzyme B (AlexaFluor700, clone GB11), 
Granzyme A (PerCP-Cy5.5, clone CB9) (BioLegend), IL10 (BV605, clone JES3–9D7) 
(BDBio-sciences). Cells were acquired on a LSRFortessa flow cytometer with Diva software 
(v6.2, BDBiosciences). A minimum of 3 × 106 events were acquired for all samples except 
for the cultures of the HIV-TB samples, there only 1 × 106 events could be acquired. 
Analysis of data was performed with FlowJo software (version9.9.6 Treestar Inc., Ashland, 
OR, USA) on a minimum of 2 × 106 CD8+ cells acquired for HD, LTBI and TB samples 
whereas only 5 × 105 CD8+ cells were analyzed in HIV-TB subjects.
Statistical analysis
Most data shown are individual patient data, lines indicate the median of the population. 
Data were analyzed using Kruskal–Wallis including multiple test correction, Wilcoxon-
Signed Rank testing and 2-way ANOVA with Dunnet’s multiple comparisons. P-values < 
0.05 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Ex vivo frequency of HLA-E restricted CD8+ T cells in HDs, LTBI, TB, and TB-HIV 
subjects. PBMCs were stained using TMs followed by viability staining and cell surface 
marker staining. Each experiment contained samples from different clinical groups, a total of 
21 experiments were performed to analyze all samples. (A) Gating strategy: Initial gate was 
on single cells, followed by selection of live cells using VIVID cell viability dye and gating 
on lymphocytes on the basis of forward-side scatters. CD3+ cells were gated as T cells and 
further selected for CD8, but not CD4 expression. (B) Representative dot plot of ex vivo TM 
staining, with a control (CMV) TM on the y-axis and the combined Mtb TMs on the x-axis. 
Dot plots show results of one HD, one LTBI, one TB-HIV coinfected patient and 3 TB 
patients. (C) Frequency and (D) memory profile analysis of ex vivo HLA-E restricted CD8+ 
T cells in HDs, LTBI, TB, and TB-HIV patients. Memory populations were defined based 
on the expression of CCR7 and CD45RA. N = naïve T cells; EM = effector memory T cells; 
CM = central memory T cells; TEMRA = T effector memory recently activated cells. For ex 
vivo analysis, event counts below <100 were not considered a TM+ population and therefore 
not included in the downstream analysis of the memory compartment. 16 out 26 HDs (11 
Dutch and 5 Italian HDs), 11 out 14 LTBI, 20 out 24 TB and 5 out 5 HIV-TB subjects were 
included in the analysis of memory subsets. Horizontal lines (C) represent median values. 
Black circles: Dutch HDs, open circles: Italian HDs, black triangles: LTBI; black squares: 
TB patients, black stars: HIV-TB. Bars represent mean values. Data shown in A-B is 
representative of 21 independent experiments with in total 71 samples and data shown in C 
and D are pooled from 21 independent experiments with —three to four donors per 
experiment. P-values were calculated using the Kruskal-Wallis test, including multiple test 
correction, ***p<0.001, ****p<0.0001. TB, LTBI and TB-HIV groups were each compared 
to the HD control group.
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HLA-E/Mtb TM+ CD8+ T-cell frequency after expansion. PBMCs were expanded using 
mitogenic stimulation, followed by magnetic bead separation of CD8+ T cells and specific 
peptide stimulation. Cells were stained with TMs first before staining with cell surface 
markers and intracellular cytokine staining. (A) Representative plots of TM staining of 
CD8+ T cells after control or combined p62 and p68 stimulation. Dot plots are representative 
of one HD and one TB patient that were analyzed in the same experiment. (B) Frequency of 
HLA-E/Mtb TM+ CD8+ T cells after PHA expansion and p62 and p68 peptide re-
stimulation. 26 out 26 HDs (13 Dutch and 13 Italian HDs), 12 out 14 LTBI, 17 out 24 active 
TB and 4 out 5 HIV-TB had sufficient cells for in vitro expansion. Black circles: Dutch HDs, 
open circles: Italian HDs, black triangles: LTBI; black squares: TB patients, black stars: 
HIV-TB. Each symbol represents one patient. P-values were calculated using Kruskal–
Wallis test including multiple-test correction. *** p<0.001. TB, LTBI and TB-HIV groups 
were compared to HD control group. —Two to three donors from different clinical groups 
were included per experiment. (C) Absolute count of TM+ events from TB patients before 
(ex vivo) and after PHA expansion and p62 and p68 re-stimulation. An average fold increase 
of 4.89 was achieved after expansion. Data were pooled from 13 culture experiments. The 
dashed horizontal line represents the cut off of 1000 cells required for in-depth analysis of 
the TM+ population, the p-value was calculated using a Wilcoxon signed rank 
test.****p<0.0001. (D) HLA-E restricted CD8+ T cells expanded with PHA and with p62 
and p68 Mtb- specific peptides were characterized for expression of TCR-Vβ16. These 
results were obtained from six independent experiments in which 6 HDs (all Dutch), 7 LTBI 
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and 8 active TB patients were included. Each symbol represents one sample and the p-value 
was calculated using a Wilcoxon-signed-rank-test. ****p<0.0001. (E) Memory profile 
analysis of HLA-E/Mtb TM+ CD8+ T cells upon PHA expansion and p62 and p68 re-
stimulation. Samples with TM+ counts <1000 were not considered for analysis of the 
memory compartment: 14 out 26 HDs (10 Dutch and 4 Italian), 6 out 13 LTBI, 15 out 17 TB 
subjects were considered in the memory analysis. Bars represent mean values.
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HLA-E/Mtb TM+ CD8+ T cells cytokine production, transcription factors, and cytolytic 
molecules. PBMCs were expanded using mitogenic stimulation, followed by magnetic bead 
separation of CD8+ T cells and specific peptide stimulation. Cells were stained with TMs 
first before staining with cell surface markers and intracellular cytokine staining. Events 
count below <1000 were not included for analysis of HLA-E restricted CD8+ T cells’ 
properties; 14 out 26 HDs (10 Dutch, 4 Italian), 6 out 13 LTBI, 15 out 17 active TB subjects 
were analyzed. P-values were calculated using a two-way ANOVA non-parametric Dunnet’s 
test multiple comparison of LTBI and TB with HD control group. Black circles: Dutch HD; 
Open circles: Italian HD; black triangles: LTBI; black squares: TB patients. (A) A 
representative plot from 21 independent experiments with —two to four samples per 
experiment show HLA-E restricted CD8+ T cells upon p62 and p68 peptide stimulation in a 
TB patient, dot plots show TM+ cells producing cytokines; transcription factors and 
cytotoxic molecules. Blue indicates expanded cells not re-stimulated with specific peptides 
(unstimulated control), red is the sample following overnight peptide stimulation. Data are 
shown for total CD8+ T cells, with the tetramer positive population on the x-axis. Donor 
TB1 is shown for IFN-γ, TNF-α, IL-4, IL-13 and the transcription factors, whereas donor 
TB12 is shown for IL-10 and the cytolytic molecules. (B) Frequency of TM+ CD8+ T cells 
producing IFNγ, TNFα, IL-4, IL-13, and IL-10 upon p62 and p68 peptide stimulation in 
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HDs, LTBIs and TB samples. 15 out 17 TB patients were analyzed, only for IL-10 (included 
in Panel B) 14 out 17 TB patients were evaluated. (C) Frequency of TM+ CD8+ T cells 
expressing T-bet, gata3 and FoxP3 transcription factors upon expansion in HDs, LTBI and 
TB subjects. (D) Frequency of TM+ CD8+ T cells producing Granulysin (Gnly), Granzyme 
A (GzmA), Granzyme B (GzmB) and Perforin (Prf). upon expansion in HDs, LTBIs and TB 
samples. In Panel B (including cytotoxic molecules) 14 out 17 active TB patients were 
analyzed. Each symbol represents one sample. Data shown in B and D are pooled from 21 
independent experiments with —two to four patients per experiment. the p-value was 
calculated using a two-way ANOVA with Dunnets’multiple comparison correction *p<0.05, 
**p<0.01, ***p<0.001.
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Comparison of HLA-E TM+ with total CD8+ T cells. PBMCs were expanded 
usingmitogenic stimulation, followed by magnetic bead separation of CD8+ T cells and 
peptide stimulation. Cells were stained with TMs before staining cell surface markers and 
intracellular cytokine staining. Total CD8+ T-cell production of IFN-γ, TNF-α, IL-4, IL-13, 
and IL-10 (A), expression of T-bet, Gata3 and FoxP3 transcription factors (B), and 
Granulysin, Granzyme A, Granzyme B and Perforin (C) was compared with the proportion 
of cells within the HLA-E/Mtb TM+ CD8+ T cells upon p62 and p68 stimulation. Lines 
connect cytokine/transcription factor expression in the same patient sample. Data are pooled 
from 21 independent experiments with —two to four patients per experiment, p-values were 
calculated using the Wilcoxon-signed-rank-test. Black stars indicate p values calculated for 
all samples (n = 37) *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; stars in square 
brackets are p-values calculated for TB subjects only (n = 15). Circles: HD; squares: TB 
patients; triangles: LTBI.
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Comparison of HLA-A*0201 and HLA-E TM+ CD8+ T cells. PBMCs were expanded using 
mitogenic stimulation, followed by magnetic bead separation of CD8+ T cells and specific 
peptide stimulation. Cells were stained with TMs first before staining with cell surface 
markers and intracellular cytokine staining. Frequency of HLA-A*0201/Mtb and HLA-
E/Mtb TM+ CD8+ T cells producing IFNγ, TNFα, IL-4, IL-13, and IL-10 (A), expressing T-
bet, Gata3 and FoxP3 transcription factors (B) and producing Granulysin, Granzyme A, 
Granzyme B and Perforin (C). 3 out 26 HDs (all Dutch), 3 out 13 LTBI, 7 out 17 active TB 
patients for panel A and 6 out 17 active TB patients for panel B were HLA-A*0201+. Data 
are pooled from 10 independent experiments with 1–3 HLA-A2+ samples per experiment. P-
values were calculated using a Wilcoxon-signed-rank-test. p-values calculated for all 
samples (n = 14; except for cytotoxic molecules & IL-10 n = 13) *p<0.05, **p<0.01, 
***p<0.001; stars in square brackets: p-values for TB subjects (n = 7). Circles: HD; squares: 
TB patients; triangles: LTBI.
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